**Name of Journal: *World Journal of Gastrointestinal Oncology***

**ESPS Manuscript NO: 26918**

**Manuscript Type: Review**

**Circular RNAs in colorectal cancer: Possible roles in regulation of cancer cells**

Taborda MI *et al.* CircRNA in colorectal cancer

**María Isabel Taborda, Sebastian Ramirez, Giuliano Bernal**

**María Isabel Taborda, Sebastian Ramirez, Giuliano Bernal,** Laboratory of Molecular and Cell Biology of Cancer (CancerLab)**,** Department of Biomedical Sciences, Faculty of Medicine, Universidad Católica del Norte, Coquimbo 1781421, Chile

**Author contributions:** Taborda MI performed the literature review, analysis and article’s writing; Ramirez S provided ideas regarding the conception of this paper and contributed with the graphic design; Bernal G contributed to this paper with a critical revision, editing and approval of the final version.

**Conflict-of-interest statement:** The authors declare no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Giuliano Bernal, PhD,** Department of Biomedical Sciences, Faculty of Medicine, Universidad Católica del Norte at Larrondo 1281, Coquimbo 1781421, Chile. gbernal@ucn.cl

**Telephone:** +56-51-2205988

**Received:** April 29, 2016

**Peer-review started:** may 4, 2016

**First decision:** July 20, 2016

**Revised:** November 5, 2016

**Accepted:** December 13, 2016

**Article in press:**

**Published online:**

**Abstract**

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world and the fourth principal cause of cancer deaths worldwide. Currently, there is a lack of low cost and noninvasive screening tests for CRC, becoming a serious health problem. In this context, a potential biomarker for the early detection of CRC has recently gained attention. Circular RNAs (circRNA), a re-discovered, abundant RNA specie, is a type of noncoding covalent closed RNAs formed from both exonic and intronic sequences. These circular molecules are widely expressed in cells, exceeding the abundance of the traditional linear mRNA transcript. They can regulate gene expression, acting as real sponges for miRNAs and also regulate alternative splicing or act as transcriptional factors and inclusive encoding for proteins. However, little is known about circRNA and its relationship with CRC. In this review, we focus on the biogenesis, function and role of these circRNAs in relation to CRC, including their potential as a new biomarker.

**Key words:** Circular RNA; colorectal cancer; gene regulation; circRNA; non-coding RNAs; long non-coding RNA; circularization

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Circular RNAs (circRNAs) are noncoding RNAs, characterized for its circularized shape. These circRNAs are abundant and might play important roles in cancer. In particular, they exhibit altered expression in colorectal cancer, and its activity as miRNA sponge might be involved in the control of cancer progression. Moreover, owing to their stability, could serve as diagnostic or predictive biomarkers for colorectal cancer.

Taborda MI, Ramirez S, Bernal G. Circular RNAs in colorectal cancer: Possible roles in regulation of cancer cells. *World J Gastrointest Oncol* 2016; In press

**INTRODUCTION**

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world (1.4 million in 2012), and the fourth principal cause of cancer deaths worldwide (694.000 deaths for both sexes)[1,2]. In terms of incidence, it represents almost 10% of global cancer diagnoses, and is the third most common cancer in males and second in females (746.000 and 614.000 respectively), with differences between developed and developing countries[2,3]. More diagnoses occur in developed regions, but less developed regions have higher death rates, reflecting a poorer rate of survival in these countries[1,3]. Sixty-five percent of the new cases occur in developed countries including the United States, Canada, Australia and Europe. In the USA in 2016, the American Cancer Society estimated over 134.000 new diagnoses of CRC (95.270 for colon, and 39.220 for rectal cancer)[2,4]. Also in 2016, CRC is expected to cause over 49.190 deaths in the United States[4].Worldwide the mortality rates are lower in women than in men, except in the Caribbean. But this tendency seems less typical in countries with higher levels of human development[2]. In contrast, CRC incidence and mortality rates in Asia are continually increasing[5]. Besides Asia, in many regions of Europe and North America, the rates of CRC incidence and mortality have decreased for both men and women, due to new screening methods allowing for early diagnosis and treatment[4–6]. These screening tests can prevent the development of CRC, as some have the potential to detect polyps before they can progress into cancer. Not all polyps will progress into cancer tumors, but their removal can prevent the disease[6].

There are several factors that contribute to the development of CRC, some of these are malleable, while others, such as genetic factors, personal medical history, age, racial and ethnic background, or preexisting conditions (inflammatory bowel disease, Lynch syndrome, MUTYH associated polyposis and others) are not[6]. CRC is primarily considered a “lifestyle” disease because its incidence is high in countries with a sedentary population and high-fat diets from animal sources[2]. An association between diet, obesity and carcinogenesis is a very important issue as several studies have shown that obesity promotes inflammatory processes, triggering a cascade of critical mechanisms mediated by proinflammatory cytokines and tumor necrosis factor-α (TNF- α), resulting in CRC development[7–9].

Three fundamental categories of genes have been identified in the carcinogenesis of CRC as follows: (1) *APC, DCC, TP53, SMAD2, SMAD4 and p16INK4a* (tumor suppressor genes); (2) *K-ras and N-ras* (proto-oncogenes); (3) *MMR* and *MUTYH* (DNA repair genes). However, little is known about the role of circular RNAs (circRNAs) in the development of CRC. Circular RNAs are a class of small group of competing endogenous RNAs (ceRNAs), in the family of the non-coding RNAs (ncRNAs) that function as a class of long non-coding RNA (lncRNA)[10–12]. These molecules have captured the interest of many in the scientific and medical communities, because hundreds of human genes are expressed in circular RNA form[13–15]. CircRNA has several functionalities, including the ability to rearrange the order of genomic information, provide protection from exonucleases, and establish constraints on RNA folding[16]. Circular RNAs can function as templates for viroid and viral replication, as intermediates in RNA processing reactions, and regulators of transcription in *cis*. Additionally, it is speculated that circRNAs serve as epigenetic microRNA (miRNA) sponges, negatively regulating miRNAs and thus contributing substantially to the ceRNAs network through RNA-binding protein (RBP) sequestering agents, or nuclear transcriptional regulators, which are frequent in cancer[16–19]. There exists evidence that most circular RNAs in the eukaryotic cell are stable, cytoplasmic, lacking the 3’ poly(A) tail and 5’ end cap, arising from pre-mRNA back-splicing exons (downstream 3’ splice donors are covalently linked to upstream 5’ splice acceptors) and host noncoding transcripts generated from protein coding genes[10,12,20–22]. Another study has found evidence that circular isoforms of several human transcripts, exhibiting the non-orderly fashion in the splice junctions, are expressed in similar concentrations to the normal linear isoform[23]. They hypothesized that scrambled exons are a sign of local genomic rearrangements in cancer, and realized this hypothesis by polymerase chain reaction (PCR), where the exon scrambling detected in leukemia patients was also found in normal primary human cell and Hela cells, suggesting that most exon scrambling found in tumor samples are consequences of an active splicing process both in normal and malignant human cells types[23]. This new type of ncRNA can be secreted by cells to the extracellular environment, and can be identified and measured through non-invasive methods, such as stool, blood and other body fluid sampling, suggesting that circRNAs could serve as an effective and cost effective screening test for CRC[15].

In this review, we discuss circRNAs, their biogenesis, possible functions, and implications in CRC.

**literature search**

A systematic literature search was performed of the PubMed database, and the keywords “circular RNA”, “circRNA” AND “cancer”, “circRNA” AND “colorectal cancer” as well other synonyms for circular RNAs, with no limitations. The inclusion criteria were as follows: (1) Reviews about CRC incidence, statistics, and features of this disease before October 2016. (2) Initial studies about circular RNAs, its biogenesis, biological functions and techniques used for its identification. (3) Studies showing the presence of circRNA in human and other species, detected using different approaches either mathematical, biochemical, biological and technological or a combination. (4) Investigations showing the expression of circRNA in different types of biological and cell samples. (5) Studies associating circRNA with biological functions and try to explain its biochemical pathway. (6) Investigations relating circRNA and CRC; including past, present and future of the disease. And (7) Studies associating circRNA with colorectal human samples or cells and discussing its potential use as biomarker for early diagnosis of the disease.

**PROPERTIES AND FUNCTIONS OF circRNAs**

In the large family of non-protein-coding RNAs, circular RNAs are a novel small group of ceRNAs, that could function as a new class of lncRNAs[10–12]. CircRNA is most often composed of exonic sequences containing one or more exons, in contrast to linear RNA which is generally formed by a covalently closed continuous loop containing a 5’-3’ phosphodiester bond and without polyadenylation[10,12,24,25]. This new type of RNA is now known to be expressed in all tissues, at generally low levels but highly represented in the eukaryotic transcriptome[19,26]. Several studies have shown that the circular form of circRNAs gives this molecule a special role in gene expression, but their biological functions have yet to be determined[17,26–29]. In 2013 it was reported that circRNAs are a common, abundant and potentially developmentally regulated component of the gene expression programs in diverse animal species[25]*.* Salzman *et al*[23]alsodemonstrated that circRNAs with scrambled exons compose a significant fraction of cellular RNA for many genes in cancer and normal human cells, suggesting also that the majority of scrambled exons detected in tumor samples were consequential of active splicing processes in both normal and malignant human cell types. Moreover, they subsequently reported that circRNA’s relative abundance is regulated, in a gene and cell type specific manner, at levels comparable to those of canonical linear mRNA, and some of these circRNA species exhibited resistance to a 3’-5’ exoribonuclease - RNase R[25]. Jeck *et al*[12] demonstrated in the same year, that there exist up to 25000 different circRNAs in human cells, and in some cases are even considerably more abundant (> 10-fold) than associated linear transcripts. Although most circRNAs are expressed at low levels, some have proved to be more abundant than their linear counterparts[25].

A distinctive property of circular RNA is they differ structurally from other lncRNAs[19]. In order to create a linear RNA transcript with polarity 5’ to 3’, the eukaryotic cell uses spliceosomal machinery in conjunction with other biochemical process (5’ capping and 3’ polyadenylation) to create a canonical pre-mRNA, removing introns and joint exons[10]. This splicing process is an ubiquitous feature of eukaryotic gene expression, and it is known that the Last Common Eukaryotic Ancestor was relatively intron-rich and had complex spliceosome machinery and splicing signals[21,22]. Conversely, most circular RNAs in the eukaryotic cell are stable, cytoplasmic, lacking the 3’ poly(A) tail and 5’ end cap, come from pre-mRNA back-splicing exons and host noncoding transcripts generated from protein coding genes[10,12,20–22]. Gou *et al*[11] examined the subcellular localization of circRNA, focusing on the 514 circRNAs detected in the K562 whole-cell samples, and found these circRNAs predominantly in the poly(A)-depleted cytoplasmic samples. Jeck *et al*[12]demonstrated by FISH onHs68 cellstreated with Actinomycin D, against HIPK3; that circular forms of HIPK3 were preferentially localized in the cytoplasm as is consistent with prior studies of RNA circles. Apparently, endogenous circular RNAs that are efficiently transported to the cytosol either undergo nuclear export or are released to the cytoplasm during mitosis, where they are extraordinarily stable[12,16,23,30]. This stability, or resistance, to debranching enzymes and RNA exonucleases[12] was also reported by Gou *et al*[11]; they found that most circRNAs that span < 5 exons are RNase R-resistant. Jeck *et al*[12] used a method described by Suzuki *et al*[31] in 2006, using *E. coli* RNase R, which degrades linear RNAs with short 3′ tails regardless of secondary structure, leaving circular RNAs unaffected[12]. Salzman *et al*[25] found that all the RNA species predicted to be circular are resistant to RNase R whereas all predicted linear sequences are highly sensitive to RNase R[25].

**BIOGENESIS AND REGULATION OF circRNAs**

CircRNAs are the product of a back-splicing process also catalyzed by canonical spliceosomal machinery, and it has been reported that this process is modulated by *cis-*regulatory elements and trans*-*acting factors, but it is still unclear under which conditions the spliceosomal machinery achieve discrimination between canonical splicing or back-splicing to give rise to a circRNA[10,16,19,20,26,32]. Ashwal *et al*[32]hasprovided evidence that circular RNA are generated co-transcriptionally and their production rate is principally mediated by their flanking intronic sequences. They also demonstrated that canonical pre-mRNA splicing compete with circularization of exons, suggesting that a single pre-mRNA transcript can produce either a linear mRNA or a circular isoform (Figure 1a). Zhang *et al*[33] indicated that the back-splicing process is generally coupled with canonical splicing, but process happens first depends on the specific spliceosomal machinery and still is under investigation. It is important to know that different types of circRNA molecules are generated by distinct mechanisms, independent of if they arise from intronic or exonic sequences[16,26].

The process by which a pre-mRNA becomes a circular RNA isoform begins with a start codon, and sometimes includes the canonical AUG of the associated linear transcript[12]. When the RNA Pol II recognizes the start codon, it transcribes the exonic circular RNA; which is produced from a downstream 5’-DSS inversely joined to an upstream 3’-ASS, resulting in a covalently closed circRNA transcript with a 3’, 5’- phosphodiester bond at the junction site[16,22,26,33,34], or through 2′-5′ linkages formed by a branch-point nucleophilic attack during splicing[35]. The specificity of this process still being studied, but is interesting to note that introns flanking mammalian circular RNAs are longer than average[23].

Two other mechanisms, direct back-splicing and lariat intermediate, have also been proposed as associated with circRNA formation from back-spliced exons [12,23]. This suggests that circular RNA synthesis is evolutionarily dynamic, providing an alternative generation of circular transcripts[33]. Furthermore, some exons that generally are flanked by longer introns (upstream or downstream), result in a less efficient splicing process. Inverted repeat elements, such as ALU, can facilitate RNA circularization in humans[12,33,34]. Zhang *et al*[33]identified the phenomenon “Alternative Circularization” (AC), in which a number of multiple exon circularization events can be produced from a single gene loci. This novel process of splicing leads to formation of multiple circRNAs with different expression levels, and it has been associated with diverse biologic processes[12,36,37]. In some events, AC leads to circRNAs retaining introns, adding an additional layer of complexity to the circular RNA transcriptome[22,25,26]. It has been suggested that the formation of these isoforms is derived from exon-skipping events. In these events, an exon-containing lariat is formed, which can then be internally spliced to create an exon circle[12,38].

The back-splicing process appears to be regulated by the ratio of circular to linear transcripts, and the relative abundance of differentially spliced circular isoforms is cell-type specific[22,25]. In general, the efficiency of the back-splicing process seems to be much lower than canonical splicing, in steady-state levels of circRNAs; but this efficiency is dependent on the presence of canonical splice sites flanking the exons[20,26,32,33]. Besides, flanking intronic sequences are the main factor determining circularization efficiency of a given exon, and this efficiency is related to the size of the intronic sequence. For example; circRNA flanked by longer introns are less efficiently spliced than other circRNA flanked by smaller introns[32]. Moreover, this circularization appears to have a negative effect on the splicing efficiency in the linear isoform and therefore on gene expression[32]. To overcome this inconvenience, most circRNAs have regulatory elements which reside in the flanking introns of circularized exons to continue with the back-splicing process and facilitate circRNA formation[10,26]. It has been shown that RBPs can regulate and promote circularization, after being recognized by regulatory elements such as short *cis* elements[26,32].

Another way to facilitate the processing of circRNAs is by RNA base pairing. Complementary short repeat elements, such as inverted ALU repeats, in the flanking introns are used to circularize some intervening exons. This mechanism suggests that the promotion of back-splicing requires for exons to collaborate with intronic repeats and join the back splice sites, thereby facilitating catalysis through base pairing[12,39]. However, in the case of base pairing, the simple presence of these inverted repeats does not necessarily mean that a circRNA will be produced with similar efficiency in all cell types[39]. It is suggested that RBPs, base pairing, and any splicing factor (*cis* regulatory elements and *trans* factors), might determine the balance between canonical RNA splicing and back-splicing processes, but whether circular RNA is produced co-transcriptionally or post-transcriptionally is still to be determined.

**FUNCTIONS OF CIRCULAR RNAS**

Little is known about circRNA biology, and a large number of possible functions have been attributed to this circular isoform. In human cells[40], another class of nuclear circular RNAs has been identified by Gardner *et al*[41]: circular intronic RNAs (ciRNAs) or stable intronic sequences RNA (sisRNA). In human cells (HeLa and human embryonic stem cells hESCs-H9), exon–intron circRNAs were reported, finding that these circRNAs, associated with the elongation Pol II machinery, act as positive regulators of Pol II transcription, suggesting a *cis*-regulatory role of noncoding intronic products in the efficient transcription of their parent coding genes[42]. CiRNAs do not function only as microRNA sponges, but, some abundant ciRNAs may be able to regulate gene expression in *trans* under certain circumstances.

A wide variety of studies have demonstrated that abnormal expressions of circRNAs are closely associated with various diseases including CRC[43–45]. It has been speculated that circRNAs form a class of post-transcriptional regulators, acting as epigenetic, highly stable miRNA sponges to compete with the endogenous RNA network, directlyaffecting the expression of any related gene (Figure 1b)[17,18,46]. CircRNA could be sequestering specific miRNA complexes and releasing them after cleavage[17]. The miRNA sponges ciRS-7 and miR-7, highly expressed in brain, interact to form a miR-7 inhibitor/sponge complex. It is possible that the competition between ciRS-7 and miR-7 effects oncogenesis[18,47]. Similarly, the testis-specific circRNA (*Sry)* regulates activity of miR-138, a tumor suppressor[17,48]. Therefore, ciRS-7 and *Sry* complex with miR-7 and miR-138, respectively, to form microRNA sponges blocking functionality, and reducing the invasiveness, metastasis and proliferation of several cancers[47].

CRC shows a negative correlation between global reduction of circular RNA and cell proliferation, suggesting that the back-splice machinery responsible for RNA circularization, is dysfunctional in tumor cells[46]. Recently, Xie *et al*[49] found an association between miR-145 and hsa\_circ\_001569 and the regulation of CRC progression.

Another circRNA, cir-ITCH acts as a miRNA sponge with an inhibitory effect on esophageal squamous cell carcinoma. Cir-ITCH stimulates ITCH levels, provoking an ubiquitin-mediated Dvl2 degradation, and inhibition of the canonical Wnt/β-catenin pathway, finally, contributing to cancer tumor advancement[50]. The expression of hsa\_circ\_001988 is downregulated in CRC, and contributes to differentiation and perineurual invasion[51]. A study in breast carcinoma cells (MDA-MB-231)[52] shows the possible functions of circ-Foxo3 (hsa\_circRNA\_104170), which binds to eight miRNAs (miR-22, miR-136\*, miR-138, miR-149\*, miR-433, miR-762, miR-3614–5p and miR-3622b–5p), as well as Foxo 3 Protein (Foxo3P) and Foxo3 mRNA. Circ-Foxo3 has a sponging effect on these miRNAs, promoting Foxo3 mRNA translation, suppressing both tumor growth and cancer cell proliferation[52].

**CircRNAs IN CRC**

Recent reviews have reported that in CRC cell lines and CRC tissues, a global reduction of circRNA abundance is observed, in comparison to healthy tissue, therefore allowing for the proliferation of CRC cells[53,54].

Circular RNAs were associated for the first time with CRC in transcripts of DCC (Deleted in CRC)[30]. In 2015, Bachmayr *et al*[46]reported a global reduction of circular RNA abundance in CRC cell lines and tumor samples, as compared to normal mucosa in patients with CRC. Using RNA-seq and the algorithm described by Memczak *et al*[21]and found by RT-qPCR, 39 circRNAs differentially expressed in the normal colon mucosa and CRC samples, in which 11 of the circRNAs were upregulated and 28 were downregulated. Interestingly, the Bachmayr’s group found that the expression of circRNAs was reduced in tumor samples (circRNA expression 27.8%) compared to normal colon mucosa samples (circRNA expression 78.1%). Similar evidence was found in 11 CRC cell lines, with even wider gaps in expression ratios[46]*.* In order to validate reduced circRNA expression in CRC compared to normal mucosa samples, they enriched circRNAs through RNase R digestion and subsequent deep sequencing, reporting 21.653 distinct back spliced junctions. This method revealed that it is impossible to ensure the detection of all circRNA, and that the actual number of circRNA species is much higher. This was also corroborated in other cell lines in a non-cancerous neo-proliferative disease, showing a similar negative correlation as the circRNA index and proliferation observed in colon tissues and cell lines[46]. Finally, the authors hypothesized that the back-splice machinery responsible for RNA circularization is dysfunctional in tumor cells due to an increased degradation by oncomiRNAs[15,46]. Recently, Wang *et al*[51]reported similar findings concerning the correlation of hsa\_circ\_001988 abundance and CRC in tumor tissue and adjacent normal mucosa from 62 CRC patients. By RT-qPCR they verified the presence of hsa\_circ\_001988 in these tissues, and it was found to be significantly downregulated in tumor tissue compared to healthy samples. The expression level of hsa\_circ\_001988 was significantly related to differentiation (*P* < 0.05) and perineural invasion (*P* < 0.05). Perineural invasion is a predictor of outcome in CRC and negatively associated with survival time and local recurrence in CRC patients. They concluded that hsa\_circ\_001988 may play a profound role in differentiation and perineural invasion and could be a potential target to regulate cytological behaviors[51]. Recently Xie *et al*[49]provided information about an up-regulated circRNA (circ\_001569) complexing with the tumor suppressor miR-145. MiR-145 has been related with patient survival after CRC diagnosis[55–57]. They explored the expression pattern of circ\_001569 by real-time PCR in 30-paired samples of CRC patients, and found expression of circ\_001569 was significantly higher in the CRC tissues and found correlation with aggressive characteristics of CRC, including distant metastasis and poor differentiation. Then to detect the function of circ\_001569 in the progression and invasion of CRC, they proceeded to over-express and silence the circular isoform in four CRC cell lines (over-expressed in SW480 and HCT116 and silenced in SW620 and LOVO). Accordingly, over-expression increased proliferative and invasive ability in circ\_001569 expressing cells, while a sharp reduction in proliferation and invasion rates was shown in circ\_001569 silenced cells. In addition, they found the level of miR-145 was significantly lower in CRC tissues[49]. Furthermore, using the bioinformatic algorithms (TargetScan, Pictar and miRANDA), along with Luciferase action, RT-qPCR and Western Blotting assays, they found that circ\_001569 increased the protein levels of E2F5, BAG4 and FMNL2 in SW480 and HCT116 cells, and knockdown of the circRNA in SW620 and LOVO cells had the opposite effect. Here, they provided evidence showing tumor promoting functions (proliferation and invasion) of circ\_001569 in CRC cells, directly inhibiting the regulatory activity of miR-145, and subsequently up-regulating its protein targets E2F5, BAG4 and FMNL2. Finally, they concluded that this interaction between miR-145 and hsa\_circ\_001569 in regulating CRC progression may provide new insights and therapeutic strategies for CRC prevention and treatment[49].

CircRNAs that have been related with CRC are shown in Table 1.

**CONCLUSION**

The information reviewed is the beginning of a better understanding of mechanisms and functions of this recently re-discovered circular isoform. CircRNAs can act as competing endogenous RNAs or miRNA sponges, regulating alternative splicing or transcription, modulating the expression of parental gene, managing local concentration of RBPs and RNAs through RNA transport. In cancer these molecules complex with miRNAs as inhibitor/sponge, with profound effects on oncogenesis and regulation of cancer pathways. It is possible that more important functions will be associated to this circular transcript in the near future. Still, the molecular mechanisms concerning the positive or negative relationship between circRNAs and miRNAs in CRC are poorly understood.

The search for a suitable circRNA biomarker for CRC is an important topic requiring further study. It is probable that the principal role of circRNAs in the progression of cancer is the modulation of the gene expression of oncogenes and or tumor suppressor genes, through the control of miRNA targets.

Summarizing, we conclude that microRNAs expression levels are regulated by circRNAs in a cell-type specific way, playing an important role in oncogenesis and the malignant behavior of cancer. Nevertheless, the function between circular RNA and cancer, as well as the regulatory mechanisms is still elusive and needs to be further explored. Someday this circular isoform might become an important biomarker with a potential use in the diagnosis, prognosis and therapy of CRC.

**REFERENCES**

1 **World Health Organization**. Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Available from: URL: <http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx>

2 **Bosman FT**, Hamilton SR, Lambert R. World Cancer Report 2014. 5.5 Colorectal Cancer. In: Stewart BW, Wild CP. World Cancer Report 2014 IARC. 2014: 560–76

3 **Ferlay J**, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;**136**:E359–86 [PMID: 25220842 DOI: 10.1002/ijc.29210]

4 **American Cancer Society**. What is Colorectal cancer? *Am Cancer Soc* 2015; 74 Available from: URL: <http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-risk-factors>

5 **Sung JJY**, Ng SC, Chan FKL, Chiu HM, Kim HS, Matsuda T, Ng SSM, Lau JYW, Zheng S, Adler S, Reddy N, Yeoh KG, Tsoi KKF, Ching JYL, Kuipers EJ, Rabeneck L, Young GP, Steele RJ, Lieberman D, Goh KL. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. *Gut* 2014;1–12 [PMID: 24647008 DOI: 10.1136/gutjnl-2013-306503]

6 **American Cancer Society.** Colorectal Cancer Facts & Figures 2014-2016. Available from: URL: <http://www.cancer.org/research/cancerfactsstatistics/colorectal-cancer-facts-figures>

7 **Devkota S**, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, Antonopoulos DA, Jabri B, Chang EB. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. *Nature* 2012;**487**:104–8 [PMID: 22722865 DOI: 10.1038/nature11225]

8 **Pietrzyk L**, Torres A, Maciejewski R, Torres K. Obesity and Obese-related Chronic Low-grade Inflammation in Promotion of Colorectal Cancer Development. *Asian Pac J Cancer Prev* 2015;**16**:4161–8 [PMID: 26028066 DOI: 10.7314/APJCP.2015.16.10.4161]

9 **Roberts DL**, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. *Annu Rev Med* 2010;**61**:301–16 [PMID: 19824817 DOI: 10.1146/annurev.med.080708.082713]

10 **Chen LL**, Yang L. Regulation of circRNA biogenesis. *RNA Biol* 2015;**12**:381–8 [PMID: 25746834 DOI: 10.1080/15476286.2015.1020271]

11 **Guo JU**, Agarwal V, Guo H, Bartel DP. Expanded identification and characterization of mammalian circular RNAs. *Genome Biol* 2014;**15**:409 [PMID: 25070500 DOI: 10.1186/PREACCEPT-1176565312639289]

12 **Jeck WR**, Sorrentino J a, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, Sharpless NE. Circular RNAs are abundant, conserved, and associated with ALU repeats. *RNA* 2013;**19**:141–57 [PMID: 23249747 DOI: 10.1261/rna.035667.112]

13 **Sänger HL**, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. *Proc Natl Acad Sci U S A* 1976;**73**:3852–6 [PMID: 1069269 DOI: **10.1073/pnas.73.11.3852]**

14 **Wang J,** Song Y-X, Ma B, Wang J-J, Sun J-X, Chen X-W, Zhao J-H, Yang Y-C, Wang Z-N. Regulatory Roles of Non-Coding RNAs in Colorectal Cancer. *Int J Mol Sci* 2015;**16**:19886–919 [PMID: 26307974 DOI: 10.3390/ijms160819886]

15 **Ragusa M**, Barbagallo C, Statello L, Condorelli AG, Battaglia R, Tamburello L, Barbagallo D, Di Pietro C, Purrello M. Non-coding landscapes of colorectal cancer. *World J Gastroenterol* 2015; **21**: 11709-11739 [PMID: 26556998 DOI: 10.3748/wjg.v21.i41.11709]

16 **Lasda E,** Parker R. Circular RNAs: diversity of form and function. *RNA* 2014;**20**:1829–42 [PMID: 25404635 DOI: 10.1261/rna.047126.114]

17 **Hansen TB,** Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J. Natural RNA circles function as efficient microRNA sponges. *Nature* 2013;**495**:384–8 [PMID: 23446346 DOI: 10.1038/nature11993]

18 **Hansen TB,** Kjems J, Damgaard CK. Circular RNA and miR-7 in Cancer. *Cancer Res* 2013;**73**:5609–12 [PMID: 24014594 DOI: 10.1158/0008-5472.CAN-13-1568]

19 **Ebbesen KK,** Kjems J, Hansen TB. Circular RNAs: Identification, biogenesis and function. *Biochim Biophys Acta* 2016;**1859**:163–8 [PMID: 26171810 DOI: 10.1016/j.bbagrm.2015.07.007]

20 **Starke S,** Jost I, Rossbach O, Schneider T, Schreiner S, Hung LH, Bindereif A. Exon circularization requires canonical splice signals. *Cell Rep* 2015;**10**:103–11 [PMID: 25543144 DOI: 10.1016/j.celrep.2014.12.002]

21 **Memczak S,** Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, Loewer A, Ziebold U, Landthaler M, Kocks C, le Noble F, Rajewsky N. Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature* 2013;**495**:333–8 [PMID: 23446348 DOI: 10.1038/nature11928]

22 **Wang PL,** Bao Y, Yee M-C, Barrett SP, Hogan GJ, Olsen MN, Dinneny JR, Brown PO, Salzman J. Circular RNA is expressed across the eukaryotic tree of life. *PLoS One* 2014;**9**:e90859 [PMID: 24609083 DOI: 10.1371/journal.pone.0090859]

23 **Salzman J**, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. *PLoS One* 2012;**7**:e30733 [PMID: 22319583 DOI: 10.1371/journal.pone.0030733]

24 **Qu S,** Yang X, Li X, Wang J, Gao Y, Shang R, Sun W, Dou K, Li H. Circular RNA: A new star of noncoding RNAs. *Cancer Lett* 2015;**365**:141–8 [PMID: 26052092 DOI: 10.1016/j.canlet.2015.06.003]

25 **Salzman J,** Chen RE, Olsen MN, Wang PL, Brown PO. Cell-type specific features of circular RNA expression. *PLoS Genet* 2013;**9**:e1003777 [PMID: 24039610 DOI: 10.1371/journal.pgen.1003777]

26 **Chen L.** The biogenesis and emerging roles of circular RNAs. *Nat Publ Gr* 2016;15–7 [PMID: 26908011 DOI: 10.1038/nrm.2015.32]

27 **Lukiw WJ.** Circular RNA (circRNA) in Alzheimer’s disease (AD). *Front Genet* 2013;**4**:307 [PMID: 24427167 DOI: 10.3389/fgene.2013.00307]

28 **Xin Z,** Ma Q, Ren S, Wang G, Li F. The understanding of circular RNAs as special triggers in carcinogenesis. *Brief Funct Genomics* 2016;elw001 [PMID: 26874353 DOI: 10.1093/bfgp/elw001]

29 **Du WW,** Yang W, Liu E, Yang Z, Dhaliwal P, Yang BB. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. *Nucleic Acids Res* 2016;**44**:2846–58 [PMID: 26861625 DOI: 10.1093/nar/gkw027]

30 **Nigro JM,** Cho KR, Fearon ER, Kern SE, Ruppert JM, Oliner JD, Kinzler KW, Vogelstein B. Scrambled exons. *Cell* 1991;**64**:607–13 [PMID: 1991322 DOI: 10.1016/0092-8674(91)90244-S]

31 **Suzuki H,** Zuo Y, Wang J, Zhang MQ, Malhotra A, Mayeda A. Characterization of RNase R-digested cellular RNA source that consists of lariat and circular RNAs from pre-mRNA splicing. *Nucleic Acids Res* 2006;**34** [PMID: 16682442 DOI: 10.1093/nar/gkl151]

32 **Ashwal-Fluss R,** Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, Evantal N, Memczak S, Rajewsky N, Kadener S. circRNA biogenesis competes with pre-mRNA splicing. *Mol Cell* 2014;**56**:55–66 [PMID: 25242144 DOI: 10.1016/j.molcel.2014.08.019]

33 **Zhang X-OO**, Wang H-BB, Zhang Y, Lu X, Chen L-LL, Yang L. Complementary Sequence-Mediated Exon Circularization. *Cell* 2014;**159**:134–47 [PMID: 25242744 DOI: 10.1016/j.cell.2014.09.001]

34 **Pasman Z,** Been MD, Garcia-Blanco MA. Exon circularization in mammalian nuclear extracts. *RNA* 1996;**2**:603–10 [PMID: 8718689]

35 **Flores R**, Grubb D, Elleuch A, Nohales M-Á, Delgado S, Gago S. Rolling-circle replication of viroids, viroid-like satellite RNAs and hepatitis delta virus: variations on a theme. *RNA Biol* 2011;**8**:200–6 [PMID: 21358283 DOI: 10.4161/rna.8.2.14238]

36 **Evsyukova I,** Somarelli J a, Gregory SG, Garcia-Blanco M a. Alternative splicing in multiple sclerosis and other autoimmune diseases. *RNA Biol* 2010;**7**:462–73 [PMID: 20639696]

37 **Faustino NA,** Cooper T a, Andre N. Pre-mRNA splicing and human disease. *Genes Dev* 2003;**17**:419–37 [PMID: 12600935 DOI: 10.1101/gad.1048803.snRNP]

38 **Zaphiropoulos PG.** Circular RNAs from transcripts of the rat cytochrome P450 2C24 gene: correlation with exon skipping. *Proc Natl Acad Sci U S A* 1996;**93**:6536–41 [PMID: 8692851 DOI: 10.1073/pnas.93.13.6536]

39 **Liang D,** Wilusz JE. Short intronic repeat sequences facilitate circular RNA production. *Genes Dev* 2014;**28**:2233–47 [PMID: 25281217 DOI: 10.1101/gad.251926.114]

40 **Li Z,** Huang C, Bao C, Chen L, Lin M, Wang X, Zhong G, Yu B, Hu W, Dai L, Zhu P, Chang Z, Wu Q, Zhao Y, Jia Y, Xu P, Liu H, Shan G. Exon-intron circular RNAs regulate transcription in the nucleus. *Nat Struct Mol Biol* 2015;**22**:256–64 [PMID: 25664725 DOI: 10.1038/nsmb.2959]

41 **Gardner EJ,** Nizami ZF, Conover Talbot J, Gall JG. Stable intronic sequence RNA (sisRNA), a new class of noncoding RNA from the oocyte nucleus of Xenopus tropicalis. *Genes Dev* 2012;**26**:2550–9 [PMID: 23154985 DOI: 10.1101/gad.202184.112]

42 **Zhang Y,** Zhang XO, Chen T, Xiang JF, Yin QF, Xing YH, Zhu S, Yang L, Chen LL. Circular Intronic Long Noncoding RNAs. *Mol Cell* 2013;**51**:792–806 [PMID: 24035497 DOI: 10.1016/j.molcel.2013.08.017]

43 **Ghosal S,** Das S, Sen R, Basak P, Chakrabarti J. Circ2Traits: a comprehensive database for circular RNA potentially associated with disease and traits. *Front Genet* 2013;**4**:283 [PMID: 24339831 DOI: 10.3389/fgene.2013.00283]

44 **Hancock JM.** Circles within circles: commentary on Ghosal et al. (2013) “Circ2Traits: a comprehensive database for circular RNA potentially associated with disease and traits”. *Front Genet* 2014;**5**:459 [PMID: 25610452 DOI: 10.3389/fgene.2014.00459]

45 **Enuka Y,** Lauriola M, Feldman ME, Sas-Chen A, Ulitsky I, Yarden Y. Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. *Nucleic Acids Res* 2015;**44**:gkv1367- [PMID: 26657629 DOI: 10.1093/nar/gkv1367]

46 **Bachmayr Heyda A,** Reiner AT, Auer K, Sukhbaatar N, Aust S, Bachleitner-Hofmann T, Mesteri I, Grunt TW, Zeillinger R, Pils D. Correlation of circular RNA abundance with proliferation - exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues. *Sci Rep* 2015;**5**:8057 [PMID: 25624062 DOI: 10.1038/srep08057]

47 **Peng L,** Yuan XQ, Li GC. The emerging landscape of circular RNA ciRS-7 in cancer (Review). *Oncol Rep* 2015;**33**:2669–74 [PMID: 25873049 DOI: 10.3892/or.2015.3904]

48 **Zhao Z-J,** Shen J. Circular RNA Participates in the Carcinogenesis and the Malignant Behavior of Cancer. *RNA Biol* 2015;**6286**:00–00 [PMID: 26649774 DOI: 10.1080/15476286.2015.1122162]

49 **Xie H,** Ren X, Xin S, Lan X, Lu G, Y L, SS Y, ZC Z, WT L, Ding Y-Q, Liang L. Emerging roles of circRNA\_001569 targeting miR-145 in the proliferation and invasion of colorectal cancer. *Oncotarget* 2014;[PMID: 27058418 DOI: 10.18632/oncotarget.8589]

50 **Li F,** Zhang L, Li W, Deng J, Zheng J, An M, Lu J, Zhou Y. Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/β-catenin pathway. *Oncotarget* 2015;**6**:6001–13 [PMID: 25749389 DOI: 10.18632/oncotarget.3469]

51 **Wang X,** Zhang Y, Huang L, Zhang J, Pan F, Li B, Yan Y, Jia B, Liu H, Li S, Zheng W. Decreased expression of hsa\_circ\_001988 in colorectal cancer and its clinical significances. *Int J Clin Exp Pathol* 2015;**8**:16020–5 [PMID: 26884878]

52 **Yang W,** Du WW, Li X, Yee AJ, Yang BB. Foxo3 activity promoted by non-coding effects of circular RNA and Foxo3 pseudogene in the inhibition of tumor growth and angiogenesis. *Oncogene* 2015;1–13 [PMID: 26657152 DOI: 10.1038/onc.2015.460]

53 **Yang Y**, Du Y, Liu X. Non-coding RNAs in Colorectal Cancer. 2016. Available from: URL: <http://link.springer.com/10.1007/978-3-319-42059-2> [DOI: 10.1007/978-3-319-42059-2]

54 **Arvelo F,** Sojo F, Cotte C. Biology of colorectal cancer. *Ecancermedicalscience* 2015;**9**:1–20 [PMID: 25932044 DOI: 10.3332/ecancer.2015.520]

55 **Li J-M**, Zhao R-H, Li S-T, Xie C-X, Jiang H-H, Ding W-J, Du P, Chen W, Yang M, Cui L. Down-regulation of fecal miR-143 and miR-145 as potential markers for colorectal cancer. *Saudi Med J* 2012;**33**:24–9 [PMID: 22273643]

56 **Slattery ML,** Wolff E, Hoffman MD, Pellatt DF, Milash B, Wolff RK. MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. *Genes Chromosomes Cancer* 2011;**50**:196–206 [PMID: 21213373 DOI: 10.1002/gcc.20844]

57 **Michael MZ,** O’ Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. *Mol Cancer Res* 2003;**1**:882–91 [PMID: 14573789]

**P-Reviewer:** Huang ZH, Lakatos PL, Sameer AS **S-Editor:** Gong ZM

**L-Editor:** **E-Editor:**

****

**Figure 1 Biogenesis and function of circRNAs.** a: In the nucleus, a single pre-mRNA transcript can produce a linear mRNA and a circular isoform[32]. These two steps, canonical splicing and back-splicing are catalyzed by canonical spliceosomal machinery (Yellow circle, “SM”). In order to create a linear RNA transcript with polarity 5’ to 3’, the eukaryotic cell uses spliceosomal machinery SM together with other biochemical process (5’ capping and 3’ polyadenylation)[10]. Following, circular RNA is produced from a downstream 5’-DSS joined reversely to an upstream 3’-ASS, resulting in a covalently closed circRNA transcript with a 3’, 5’- phosphodiester bond at the junction site (Figure 1)[16,22,26,33,34] and it seems to be modulated by *cis-*regulatory elements and *trans-*acting factors[10,16,19,20,26,32]. The final products of these processes are a linear mRNA, a circRNA, and an intron lariat. b: Endogenous circular RNAs that are efficiently transported to the cytosol either undergo nuclear export or are released to the cytoplasm during mitosis, where are they are extraordinarily stable[12,16,23,30]. In the cytoplasm circRNAs form a class of post-transcriptional regulators, acting as highly stable epigenetic miRNA sponges competing with the endogenous RNA network (sequestering miRNAs from binding mRNA targets), directlyaffecting the expression of any related gene[17,18,46].

**Table 1 Circular RNA found to date in colorectal cancer**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Name** | **Location** | **Length [nt]** | **Tissue/cell line associated** | **Dysregulation** | **Gene** | **miRNA Associated** | **Ref.** |
| DCC | chr18 | 177,272,334 | HCT116, H82 | None | *DCC* | None | [30] |
| circ0817circ3204circ6229circ7374circ7780 | chr11:107916,996,107,925,682chr15:63,824,845,63,855,207chr14:21,971,315,21,972,024chr17:38,638,380,38,638,668chr7:153,555,574,153,562,132 | 629-706629-706629-706288317 | Healthy and tumor mucosa | DownregulatedDownregulatedDownregulatedUpregulatedDownregulated | *CUL5**USP3**METTL3**TNS4**-* | NoneNoneNoneNoneNone | [46] |
| has\_circ\_001988 | chr4q3 | - | CRC tissue and normal mucosa | Downregulated | *CDR1as* | miRNA-7 | [21,51] |
| has\_circ\_001569 | chr16q13.1 | - | CRC and adjacent healthy tissue | Upregulated | *ABCC1* | miRNA-145 | [49] |

CRC: Colorectal cancer.